Sona Nanotech Inc
OTCQB:SNANFView on Canadian Exchange

  • LAST PRICE
    0.1965
  • TODAY'S CHANGE (%)
    0.0141 (7.7029%)
  • Bid / Lots
    0.1360/ 50
  • Ask / Lots
    0.2100/ 25
  • Open / Previous Close
    0.1900 / 0.1824
  • Day Range
    0.1900
    0.2030
  • 52 Week Range
    0.1330
    0.4075
  • Volume
    30,447

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 7, 2024

      Show headlines and story abstract

    • 8:16AM ET on Thursday Nov 07, 2024 by Newsfile
      Companies Mentioned: SNANF

      Halifax, Nova Scotia--(Newsfile Corp. - November 7, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that its Chief Scientific Officer, Dr. Len Pagliaro, has been invited to showcase Sona's developing Targeted Hyperthermia Therapy ("THT") cancer treatment today at the Nanotechnology Characterization Laboratory ("NCL"). Sona will be one of six commercial and academic collaborators to present its research at the NCL's 20th anniversary "Advancing Medical Applications of Cancer Nanotechnology" symposium. Sona's subsidiary was previously selected for the NCL Assay Cascade Program, the premier program in the World for bringing nanomaterials through critical preclinical stages and facilitating regulatory review, in which Sona's materials were assessed for biocompatibility. The NCL was established by the National Cancer Institute ("NCI") to accelerate the progress of nanomedicine by providing preclinical characterization and safety testing of nanoparticles. The NCL is a collaborative effort between NCI, the U.S. Food and Drug Administration ("FDA"), and the National Institute of Standards and Technology.

    • 8:16AM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: SONA

      Halifax, Nova Scotia--(Newsfile Corp. - November 7, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that its Chief Scientific Officer, Dr. Len Pagliaro, has been invited to showcase Sona's developing Targeted Hyperthermia Therapy ("THT") cancer treatment today at the Nanotechnology Characterization Laboratory ("NCL"). Sona will be one of six commercial and academic collaborators to present its research at the NCL's 20(th) anniversary "Advancing Medical Applications of Cancer Nanotechnology" symposium. Sona's subsidiary was previously selected for the NCL Assay Cascade Program, the premier program in the World for bringing nanomaterials through critical preclinical stages and facilitating regulatory review, in which Sona's materials were assessed for biocompatibility. The NCL was established by the National Cancer Institute ("NCI") to accelerate the progress of nanomedicine by providing preclinical characterization and safety testing of nanoparticles. The NCL is a collaborative effort between NCI, the U.S. Food and Drug Administration ("FDA"), and the National Institute of Standards and Technology.

  • Oct 21, 2024

      Show headlines and story abstract

    • 4:33PM ET on Monday Oct 21, 2024 by Newsfile
      Companies Mentioned: SNANF

      Halifax, Nova Scotia--(Newsfile Corp. - October 21, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce the issuance of U.S. Patent No. 12117447 by the U.S. Patent and Trademark Office to the Company, entitled, "Metal Nanoparticles and Methods of Making Same". This patent covers the Company's proprietary process for manufacturing gold nanorods without the use of the toxic substance, cetyltrimethylammonium bromide ("CTAB"), which typically carries significant cytotoxic and genotoxic risks.

    • 4:33PM ET on Monday Oct 21, 2024 by Dow Jones
      Companies Mentioned: SONA

      Halifax, Nova Scotia--(Newsfile Corp. - October 21, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce the issuance of U.S. Patent No. 12117447 by the U.S. Patent and Trademark Office to the Company, entitled, "Metal Nanoparticles and Methods of Making Same". This patent covers the Company's proprietary process for manufacturing gold nanorods without the use of the toxic substance, cetyltrimethylammonium bromide ("CTAB"), which typically carries significant cytotoxic and genotoxic risks.

Peers Headlines

No documents available